Eli Lilly can reinvest its GLP-1 cash flow into biological intelligence, building on the growth of its metabolic drugs. AI agent swarms working on scientific problems underpin the view that Lilly is becoming the world's most important AI company and could be the largest US company by decade's end. 2027 will be a year of cures and AI-driven scientific breakthroughs. x.com 

Eli Lilly's broader biology opportunity leaves far more upside than most appreciate. Q3 earnings crushed estimates as expected: revenue was $24.4B versus $22.6B expected, and adjusted EPS was $7.48 versus $6.50. GLP-1s fund its longer-term drug-discovery platform rather than defining the whole thesis. x.com 

Ginkgo Bioworks is not investable right now; it is better to wait for execution and de-risking and buy at a higher valuation. AI and robotics are good for biology, and OpenAI partnered with Ginkgo this year. But @JackPrescottX notes Ginkgo has roughly seven quarters of runway and must grow revenue within two years or face heavy dilution or bankruptcy. x.com 

Eli Lilly's GLP-1 and metabolic franchise can compound demand and cash flows while rate fears punish leveraged AI stories. It is preferable as a defensive-growth holding into its October 29 earnings over chasing a chip bounce. Continued healthcare volume leadership would support the sleeve; if semiconductors reclaim leadership first, the rotation is already crowded the other way. x.com  x.com 

Nvidia, Broadcom, TSMC, Microsoft and Eli Lilly are top stocks for the next decade, powered by tailwinds in semiconductors, cloud AI and next-generation healthcare as the AI revolution is just getting started. Nvidia is the AI GPU leader, Broadcom supplies custom AI chips and cybersecurity, TSMC is the foundry fueling it all, Microsoft pairs Azure with AI software, and Lilly rides GLP-1 drugs. x.com 

Ginkgo Bioworks is too speculative to own, even as it shifts from a failed synthetic biology model, with the stock down about 99% from highs, toward robotics and AI-driven dark labs. Multiple expert calls suggest the automation tech is viable and differentiated, and with about $150mm of annual burn it has a few years of runway. At roughly $220mm EV the risk/reward looks favorable but highly non-concrete, because traction is still early. x.com  x.com 

Eli Lilly is well positioned for an AI-driven biotech boom, and strong Q2 results back that up. Revenue reached $22.97B against $20.59B expected, with Zepbound at $4.93B and Mounjaro at $9.9B both ahead of estimates. Lilly raised full-year revenue guidance to $85-87B from $82-85B and committed an additional $4.5B to expand manufacturing. x.com  x.com 

Eli Lilly is priced for perfection, but it just might be perfection. A new Nvidia partnership builds lab infrastructure on the BioNeMo platform and Vera Rubin accelerators, using robotics and physical AI to superscale drug discovery and production. Lilly is rumored to be acquiring Insilico Medicine, one of the best AI biology platforms, and retatrutide is delivering outstanding weight loss in the clinic. x.com 

AI drug-discovery picks and shovels such as Ginkgo Bioworks, 10x Genomics, Twist Bioscience and Grail are priced on a fantasy, and secondary offerings are coming. The bet that AI will solve cancers and rare diseases within months ignores how drug discovery, regulation and trial enrollment actually work. Unlike the semiconductor comparison, these businesses have not inflected, mostly burn cash, trade at 20-30x sales and need equity to fund themselves. Buyers here become their liquidity. x.com  … Show more

AI's application layer remains the long-term bet: after 24 months in infrastructure on obvious earnings, capital must now move to the layer that produces durable economic value. Tempus AI's edge is proprietary data, which stays scarce as raw intelligence gets cheaper. Eli Lilly's LillyPod pairs 1,000 Blackwell GPUs with decades of clinical data, an underrated moat. Lemonade's tech yields cost, price and growth edges. Coinbase provides the stablecoin financial guardrails agentic AI needs. x.com